Carregant...
The impact of early phase trial design in the drug development process
PURPOSE: Many of the therapeutic agents that are being used currently were developed using the 3+3 decision rule for dose-finding. Over the past 30 years, several dose-finding designs have been proposed and evaluated, including the ‘continual reassessment method’ (CRM) and the ‘Bayesian optimal inte...
Guardat en:
| Publicat a: | Clin Cancer Res |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6335181/ https://ncbi.nlm.nih.gov/pubmed/30327310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0203 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|